АНАЛИЗ РОССИЙСКОГО РЫНКА ЛЕКАРСТВЕННЫХ ПРЕПАРАТОВ, ПРИМЕНЯЕМЫХ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, ПЕРЕДАЮЩИХСЯ ПОЛОВЫМ ПУТЕМ

Abstract

Sexually transmitted diseases (STDs) are the category of diseases that infected during sexual intercourse. Today, unfortunately, despite the decrease in the level of general morbidity, the structure of the incidence of STDs is changing, which forces us to return to solving this problem again. Diseases of this group not only spread very easily, but also cause harm to both the genitals and the body as a whole. As a result, human health deteriorates, the function of the reproductive system suffers, which also affects the health of future offspring. To minimize the above consequences, the Russian pharmaceutical market (RPhM) has a large assortment portfolio of medicines with various groups. So, in particular, many medicines are included in the List of vital and essential medicines(VEM) and in the minimum assortment list, according to the decree of the Government of the Russian Federation dated 12.10.2019 No. 2406-r "On approved The list of vital VEM for 2023, as well as lists of medicines for medical use and the minimum range of medicines necessary for the provision of medical care". A similar study was conducted in order to analyze the range of RPhM drugs used for the treatment of STDs. During the research, various official information sources on medicines registered in the territory of the Russian Federation used for the treatment of STDs were reviewed and studied: the Register of Medicines of Russian Federation "RADAR" (2023), the State Register of Medicines and Medical Devices (2023), the Vidal handbook of medicines "Medicines in Russian Federation" (2023), orders of the Government of the Russian Federation, Internet sources. Research methods: structural, graphical, comparative, content analysis, segmentation.